Philip D. Yin

1.4k total citations
14 papers, 299 citations indexed

About

Philip D. Yin is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Philip D. Yin has authored 14 papers receiving a total of 299 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hepatology, 5 papers in Epidemiology and 4 papers in Infectious Diseases. Recurrent topics in Philip D. Yin's work include Hepatitis C virus research (8 papers), HIV/AIDS drug development and treatment (4 papers) and HIV Research and Treatment (3 papers). Philip D. Yin is often cited by papers focused on Hepatitis C virus research (8 papers), HIV/AIDS drug development and treatment (4 papers) and HIV Research and Treatment (3 papers). Philip D. Yin collaborates with scholars based in United States, France and United Kingdom. Philip D. Yin's co-authors include Wei-Shau Hu, Jeffrey A. Anderson, Ronald J. Teufel, Eric Hughes, Fiona McPhee, Debananda Das, K. Tsuchiya, Kenji Maeda, Lauren Hackney and Yoshikazu Takaoka and has published in prestigious journals such as Gastroenterology, Journal of Molecular Biology and Hepatology.

In The Last Decade

Philip D. Yin

14 papers receiving 288 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philip D. Yin United States 9 144 121 92 83 68 14 299
Rumana Azad United States 4 217 1.5× 63 0.5× 48 0.5× 34 0.4× 234 3.4× 6 431
Dennis Revie United States 9 137 1.0× 118 1.0× 155 1.7× 117 1.4× 75 1.1× 12 341
Daitze Wu China 9 184 1.3× 138 1.1× 109 1.2× 46 0.6× 102 1.5× 14 320
Janina Bruening Germany 8 101 0.7× 169 1.4× 108 1.2× 30 0.4× 55 0.8× 11 313
Margaret Robinson United States 8 306 2.1× 291 2.4× 93 1.0× 62 0.7× 142 2.1× 13 424
Virginia Chu United States 6 115 0.8× 176 1.5× 65 0.7× 22 0.3× 150 2.2× 6 368
Gaëtan Ligat France 11 257 1.8× 102 0.8× 67 0.7× 30 0.4× 58 0.9× 20 317
Michael Foss France 6 154 1.1× 105 0.9× 37 0.4× 32 0.4× 83 1.2× 22 313
Olivier Vidalin France 8 249 1.7× 306 2.5× 53 0.6× 48 0.6× 69 1.0× 8 413
Senthil Chinnakannan United Kingdom 10 176 1.2× 94 0.8× 82 0.9× 34 0.4× 53 0.8× 17 273

Countries citing papers authored by Philip D. Yin

Since Specialization
Citations

This map shows the geographic impact of Philip D. Yin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip D. Yin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip D. Yin more than expected).

Fields of papers citing papers by Philip D. Yin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip D. Yin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip D. Yin. The network helps show where Philip D. Yin may publish in the future.

Co-authorship network of co-authors of Philip D. Yin

This figure shows the co-authorship network connecting the top 25 collaborators of Philip D. Yin. A scholar is included among the top collaborators of Philip D. Yin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip D. Yin. Philip D. Yin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
Kao, Jia‐Horng, Ming‐Lung Yu, Chung‐Kang Peng, et al.. (2017). Daclatasvir/asunaprevir/beclabuvir, all‐oral, fixed‐dose combination for patients with chronic hepatitis C virus genotype 1. Journal of Gastroenterology and Hepatology. 32(12). 1998–2005. 9 indexed citations
3.
Sulkowski, Mark, S. Flamm, Zeid Kayali, et al.. (2016). Short‐duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study). Liver International. 37(6). 836–842. 23 indexed citations
4.
5.
Zhou, Nannan, Dennis Hernandez, Xiaoyan Yang, et al.. (2015). NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection. The Journal of Infectious Diseases. 213(2). 206–215. 25 indexed citations
6.
Hézode, Christophe, Laurent Alric, Ashley C. Brown, et al.. (2015). Randomized Controlled Trial of the NS5A Inhibitor Daclatasvir plus Pegylated Interferon and Ribavirin for HCV Genotype-4 (COMMAND-4). Antiviral Therapy. 21(3). 195–205. 18 indexed citations
7.
Kowdley, Kris V., David R. Nelson, Jacob Lalezari, et al.. (2015). Tu1013 On-Treatment HCV RNA As a Predictor of Sustained Virologie Response in HCV Genotype 3 - Infected Patients Treated With Daclatasvir and Sofosbuvir: Analysis of Phase 3 Ally-3 Study. Gastroenterology. 148(4). S–1084. 1 indexed citations
8.
Hézode, Christophe, Laurent Alric, Ashley Brown, et al.. (2014). 819Daclatasvir in Combination with Peginterferon Alfa-2a and Ribavirin for Treatment-Naive Patients with HCV Genotype 4 Infection: Phase 3 COMMAND-4 Results. Open Forum Infectious Diseases. 1(suppl_1). S233–S233. 5 indexed citations
9.
Ahmad, Tariq, Philip D. Yin, Jeffrey E. Saffitz, et al.. (2014). Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology. 62(2). 409–416. 56 indexed citations
10.
Maeda, Kenji, Debananda Das, Philip D. Yin, et al.. (2008). Involvement of the Second Extracellular Loop and Transmembrane Residues of CCR5 in Inhibitor Binding and HIV-1 Fusion: Insights into the Mechanism of Allosteric Inhibition. Journal of Molecular Biology. 381(4). 956–974. 51 indexed citations
11.
Yin, Philip D., Shree K. Kurup, Steven H. Fischer, et al.. (2007). Progressive outer retinal necrosis in the era of highly active antiretroviral therapy: Successful management with intravitreal injections and monitoring with quantitative PCR. Journal of Clinical Virology. 38(3). 254–259. 32 indexed citations
12.
Anderson, Jeffrey A., Ronald J. Teufel, Philip D. Yin, & Wei-Shau Hu. (1998). Correlated Template-Switching Events during Minus-Strand DNA Synthesis: a Mechanism for High Negative Interference during Retroviral Recombination. Journal of Virology. 72(2). 1186–1194. 49 indexed citations
13.
Yin, Philip D., et al.. (1998). Nonreciprocal Pseudotyping: Murine Leukemia Virus Proteins Cannot Efficiently Package Spleen Necrosis Virus-Based Vector RNA. Journal of Virology. 72(7). 5408–5413. 23 indexed citations
14.
Anderson, James C., et al.. (1997). Seismic behavior of a high-strength concrete framed tube. The Structural Design of Tall Buildings. 6(4). 333–350. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rumana Azad Breakdown of academic impact, for papers by Dennis Revie Breakdown of academic impact, for papers by Daitze Wu Breakdown of academic impact, for papers by Janina Bruening Breakdown of academic impact, for papers by Margaret Robinson Breakdown of academic impact, for papers by Virginia Chu Breakdown of academic impact, for papers by Gaëtan Ligat Breakdown of academic impact, for papers by Michael Foss Breakdown of academic impact, for papers by Olivier Vidalin Breakdown of academic impact, for papers by Senthil Chinnakannan
Rankless by CCL
2026